Akari Therapeutics, PLC
AKTXAkari Therapeutics, PLC in brief
Akari Therapeutics, PLC is a listed company in the Biotechnology industry, based in Tampa, Florida, USA. Its market value was $13 M on 1 August 2026, which makes it the 25,367th largest listed company in the world and the 4,238th largest in the USA on this site. It employs about 6 people and Abizer Gaslightwala is its chief executive. Its shares trade under the symbol AKTX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Akari Therapeutics, PLC
We are an oncology company developing next-generation antibody-drug conjugates built around novel, proprietary payloads utilizing powerful biology to attack cancer. Our lead payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. PH1’s disruption of normal RNA splicing has multiple modes of action on cancer cells: 1) cell killing and cytotoxicity that causes cancer cell death and 2) generates neoantigen proteins that activates both the innate and adaptive immune systems to drive robust and durable cancer killing activity in preclinical models. Additionally, AKTX-101 is active against urothelial cancers with FGFR3- fusions, lung cancers with SMARCA4 deletions and BRAF G466V mutations, and K-Ras G12V driven pancreatic cancers, whereas the PH1 payload has been demonstrated to be active against metastatic prostate cancer cells driven by AR-v7 and AR-hormone dependent prostate cancer showing the power of the PH1 payload against oncogenes derived from spliced isoforms/variants. Utilizing the novel PH1 payload as a platform, the Company has the ability to generate a pipeline of ADC candidates each focused on a different cancer antigen target of interest (i.e. Trop-2, CEACAM5). Akari’s lead candidate, AKTX-101, targets the Trop-2 receptor on cancer cells and is engineered with a proprietary linker to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative in animal models relative to an ADC with a traditional payload (topoisomerase1 inhibitor).
From the company's annual report filed with the US SEC: read the report
Akari Therapeutics, PLC timeline
- 2012
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2013
- ✎Renamed Celsus Therapeutics Plc.Formerly Morria Biopharmaceuticals PLC.
- 2014
- 🔔Initial public offering as Celsus Therapeutics Plc.Final prospectus filed with the SEC on 31 January 2014; shares registered for exchange trading on 30 January 2014.
- 2015
- ✎Renamed Akari Therapeutics PlcFormerly Celsus Therapeutics Plc..
Events of Akari Therapeutics, PLC from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,257 (Jan 2020) · #3,880 (Jan 2021) · #4,702 (Jan 2022) · #5,138 (Dec 2022) · #5,150 (Jul 2023) · #4,446 (Jan 2024) · #2,360 (Mar 2026) · #4,010 (Aug 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.5×
- Free cash flow yield
- -126.4%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -61.1%
- Liabilities / assets
- 40.8%
- Revenue growth
- -39.3%
- R&D / revenue
- 1473.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-17M | $-17M | — |
| Dec 2024 | — | — | $-22M | $-20M | — |
| Dec 2023 | $0M | -39.3% | $-17M | $-10M | -2705.4% |
| Dec 2022 | $1M | — | $-12M | $-13M | -2145.9% |
| Dec 2021 | — | — | $-17M | $-17M | — |
| Dec 2020 | — | — | $-18M | $-17M | — |
| Dec 2019 | — | — | $-17M | $-17M | — |
| Dec 2018 | — | — | $-21M | $-21M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-11M | — | — | $0.00 | — |
| Dec 2024 | $-13M | — | — | $0.00 | — |
| Dec 2023 | $-16M | $0M | $-16M | $0.00 | — |
| Dec 2022 | $-7M | $0M | $-8M | $-0.74 | — |
| Dec 2021 | $-19M | — | — | $0.00 | — |
| Dec 2020 | $-17M | — | — | $-0.01 | — |
| Dec 2019 | $-13M | $0M | $-13M | $-0.01 | — |
| Dec 2018 | $-23M | $0M | $-23M | $-0.01 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Oct 30, 20268-KCurrent reportShareholder vote
- Oct 1, 2026DEF 14AProxy statement
- Oct 1, 20268-KCurrent reportDirectors or officers changed
- Aug 13, 20268-KCurrent reportResults of operations
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Jul 2, 20268-KCurrent reportShareholder vote
- Jun 26, 20268-KCurrent reportMaterial agreement
- Jun 26, 2026S-1/AIPO registration (amended)
- Jun 4, 2026DEF 14AProxy statement
- May 22, 20268-KCurrent reportMaterial agreement · Unregistered share sale
Official filings of Akari Therapeutics, PLC with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-17 M
- Net income
- $-17 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $48 M
- Total liabilities
- $20 M
- Total equity
- $28 M
As of December-2025
Top 13 institutional investors in Akari Therapeutics, PLC#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vestmark Advisory Solutions, Inc. | 37,688 | New | 2.28% | $0 M | Nov 16, 2026 |
| 2 | Jane Street Group, LLC | 23,242 | +7,779 (+50.31%) | 1.41% | $0 M | Nov 12, 2026 |
| 3 | Citadel Advisors LLC | 21,637 | New | 1.31% | $0 M | Nov 16, 2026 |
| 4 | Cresset Asset Management, LLC | 20,561 | 0 (0.00%) | 1.24% | $0 M | Nov 16, 2026 |
| 5 | Occidental Asset Management, LLC | 18,125 | New | 1.10% | $0 M | Nov 5, 2026 |
| 6 | MMCAP International Inc. SPC | 11,427 | -88,573 (-88.57%) | 0.69% | $0 M | Nov 12, 2026 |
| 7 | GAMMA Investing LLC | 2,411 | New | 0.15% | $0 M | Oct 8, 2026 |
| 8 | Tower Research Capital LLC (TRC) | 385 | New | 0.02% | $0 M | Nov 16, 2026 |
| 9 | IFP Advisors, Inc | 181 | 0 (0.00%) | 0.01% | $0 M | Oct 16, 2026 |
| 10 | Nuveen, LLC | 86 | New | 0.01% | $0 M | Nov 10, 2026 |
| 11 | SBI Securities Co., Ltd. | 15 | +1 (+7.14%) | 0.00% | $0 M | Oct 22, 2026 |
| 12 | Caitong International Asset Management Co., Ltd | 10 | +2 (+25.00%) | 0.00% | $0 M | Oct 29, 2026 |
| 13 | Northwestern Mutual Wealth Management Co | 7 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
Insider trading at Akari Therapeutics, PLC#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Abizer GaslightwalaCEO, Director | Option exercise | +19,333 | $0.000 | $8 | 33,440 | Form 4 |
| filed | Abizer GaslightwalaCEO, Director | Option exercise | +7,733 | $0.000 | $3 | 41,173 | Form 4 |
| filed | Robert B. BazemoreDirector | Option exercise | +773 | $0.000 | $0 | 19,666 | Form 4 |
| filed | Sandip I. PatelDirector | Option exercise | +3,866 | $0.000 | $2 | 32,691 | Form 4 |
| filed | Robert B. BazemoreDirector | Option exercise | +3,093 | $0.000 | $1 | 22,759 | Form 4 |
| filed | Sandip I. PatelDirector | Option exercise | +6,186 | $0.000 | $2 | 38,877 | Form 4 |
| filed | Samir Rashmikant PatelDirector | Grant or award | +2,236 | $7.899 | $18 K | 12,102 | Form 4 |
| filed | Robert B. BazemoreDirector | Grant or award | +4,677 | $7.899 | $37 K | 18,893 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Akari Therapeutics, PLC#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-11-18 15:42 UTC, code LUDP, resumed 15:52 UTC
- 2026-11-18 15:18 UTC, code LUDP, resumed 15:29 UTC
- 2026-05-28 13:55 UTC, code LUDP, resumed 14:05 UTC
- 2026-05-26 15:17 UTC, code LUDP, resumed 15:22 UTC
- 2026-05-26 14:00 UTC, code LUDP, resumed 14:05 UTC
Fails to deliver
- : 3,419 shares at $8.53
- : 3,238 shares at $9.20
- : 2,931 shares at $8.58
- : 24 shares at $8.23
- : 1,624 shares at $8.76
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Akari Therapeutics, PLC scorecard#
Passes 0 of the 9 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year0.00 vs 0.00Diluted EPS 0.00 in fiscal 2025 against 0.00 the year before (report's currency).
- ✗Net income higher than five years earlier-$17 M-$17 M in fiscal 2025 against -$17 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$17 MNet income -$17 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-68.4%-68.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 3
- ✗Short-term assets cover short-term liabilities0.4×Current ratio 0.44 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-172.8×Operating income -172.8 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year181.8%Diluted shares up 181.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Akari Therapeutics, PLC: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Research and development | 2.8−59.7%— | 7.0+28.1%— | 5.5−43.0%— | 9.6r9.6+4.7%— | 9.1+3.6%— | 8.8+0.9%— | 8.7−25.9%— | 12−49.3%— | 23+34.6%— | 17—— | |
| Selling, general and administrative | 9.3−4.0%— | 9.7−14.9%— | 11−16.0%— | 14r14+67.4%— | 8.1−11.8%— | 9.2+11.4%— | 8.2−29.7%— | 12r11−0.9%— | 12+18.7%— | 9.9—— | |
| Operating expenses | 17−20.2%— | 22+28.8%— | 17−27.2%— | 23+34.1%— | 17−4.3%— | 18+6.0%— | 17−18.4%— | 21r20−45.0%— | 38+38.7%— | 27—— | |
| Operating income | −17—— | −22—— | −17—— | −23r−23—— | −17—— | −18—— | −17—— | −21r−20—— | −38—— | −27—— | |
| Interest and finance income | 0.0−87.5%— | 0.0−90.2%— | 0.1+78.3%— | 0.0r0.0+334%— | 0.0−22.1%— | 0.0+146%— | 0.0−97.5%— | 0.2+26.7%— | 0.2+22.5%— | 0.1—— | |
| Interest expense and finance costs | 0.1−59.0%— | 0.2—— | — | — | — | — | — | — | 0—— | 0—— | |
| Other non-operating income (expense) | −1.0−155%— | 1.9−72.8%— | 6.8r−0.0+27.3%— | 5.3—— | −0.2−123%— | 0.9+669%— | 0.1r−0.1−59.1%— | 0.3r3.5−88.0%— | 2.4−73.8%— | 9.1—— | |
| Income before tax | −18—— | −20—— | −10r−0.0—— | −0.0r−18—— | −17—— | −17—— | −17r−17—— | −20r−16—— | −35—— | −18—— | |
| Income tax | −1.0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | |
| Net income attributable to shareholders | −17—— | −20—— | −10—— | −18r−18—— | −17—— | −17—— | −17r−17—— | −20r−16—— | −35—— | −18—— | |
| Earnings per share, basic | 0.00—— | 0.00—— | 0.00—— | 0.00—— | 0.00—— | -0.01—— | -0.01—— | -0.01—— | -0.03—— | -0.02—— | |
| Earnings per share, diluted | 0.00—— | 0.00—— | 0.00—— | 0.00—— | 0.00—— | -0.01—— | -0.01—— | -0.01—— | -0.03—— | -0.02—— | |
| Shares, weighted average (basic) | 67,328+182%— | 23,888+144%— | 9,789+56.8%— | 6,243+45.5%— | 4,292+35.9%— | 3,159+72.5%— | 1,831+18.9%— | 1,540+23.5%— | 1,247+5.9%— | 1,178—— | |
| Shares, weighted average (diluted) | 67,328+182%— | 23,888+144%— | 9,789+56.8%— | 6,243+45.5%— | 4,292+35.9%— | 3,159+72.5%— | 1,831+18.9%— | 1,540+23.5%— | 1,247+5.9%— | 1,178—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 5.2r0—10.9% | 0r2.6−100%0.0% | 3.8−71.0%88.3% | 13r13+41.5%95.8% | 9.4−33.4%80.4% | 14+145%96.2% | 5.7+5.2%88.5% | 5.4−80.6%67.8% | 28−17.6%96.8% | 34—74.3% | |
| Short-term investments | — | — | — | — | — | — | — | — | 0−100%0.0% | 10—21.8% | |
| Other current assets | 0.0−93.0%0.0% | 0.2+2.0%0.4% | 0.2+97.0%4.5% | 0.1r0.1+10.7%0.7% | 0.1−60.6%0.8% | 0.2r0.5−67.9%1.6% | 0.7−49.9%11.0% | 1.4+101%17.7% | 0.7−53.3%2.4% | 1.5—3.3% | |
| Current assets | 5.5+85.0%11.4% | 3.0−32.0%5.8% | 4.3−68.6%99.7% | 14r14+18.8%99.9% | 12−20.3%99.8% | 15+126%99.8% | 6.4r6.8−13.5%99.5% | 7.5−74.1%92.8% | 29−36.9%99.2% | 46—99.5% | |
| Property, plant and equipment | — | — | — | 0—0.0% | 0—0.0% | 0−100%0.0% | 0.0−75.5%0.1% | 0.0−63.5%0.3% | 0.1−4.2%0.2% | 0.1—0.1% | |
| Goodwill | 8.40.0%17.6% | 8.4—16.7% | — | — | — | — | — | — | — | — | |
| Other intangible assets | — | — | 0.0−17.6%0.3% | 0.0r0.0−25.9%0.1% | 0.0−15.5%0.2% | 0.0−10.0%0.2% | 0.0−8.5%0.5% | 0.0−15.7%0.4% | 0.0−0.6%0.1% | 0.0—0.1% | |
| Total assets | 48−5.3%100% | 51+1061%100% | 4.4−68.5%100% | 14r14+18.7%100% | 12−20.2%100% | 15+125%100% | 6.5r6.8−19.3%100% | 8.0−72.4%100% | 29−36.7%100% | 46—100% | |
| Accounts payable | 8.8−29.3%18.3% | 12+642%24.5% | 1.7+76.5%38.4% | 0.9r0.9−47.1%6.8% | 1.8−47.1%15.4% | 3.4+175%23.1% | 1.2−22.5%19.0% | 1.6−19.5%19.8% | 2.0−11.0%6.8% | 2.2—4.8% | |
| Current liabilities | 12−38.0%25.8% | 20+334%39.4% | 4.6—105% | — | — | — | — | 4.9−58.5%61.3% | 12+1.1%40.8% | 12—25.5% | |
| Non-current liabilities | — | — | — | — | — | — | — | 0−100%0.0% | 0.0−14.8%0.2% | 0.1—0.1% | |
| Total liabilities | 20−30.9%40.9% | 28+518%56.0% | 4.6−61.9%105% | 12r12+97.6%87.1% | 6.1+16.7%52.3% | 5.2−19.3%35.7% | 6.5r8.6+31.6%99.9% | 4.9−58.7%61.3% | 12+1.1%41.0% | 12—25.7% | |
| Retained earnings | −265—−552% | −247—−489% | −227—−5223% | −217r−217—−1572% | −200—−1714% | −182—−1248% | −165r−144—−2549% | −127—−1579% | −110—−380% | −75—−163% | |
| Shareholders' equity | 28+27.4%59.1% | 22—44.0% | −0.2−113%−5.3% | 1.8r1.8−67.8%12.9% | 5.6r5.6−40.8%47.7% | 9.4+123410%64.3% | 0.0r−1.8−99.8%0.1% | 4.4r3.1−80.4%54.4% | 22r17−34.8%76.5% | 34—74.3% | |
| Total liabilities and equity | 48−5.3%100% | 51+1061%100% | 4.4−68.5%100% | 14r14+18.7%100% | 12−20.2%100% | 15+125%100% | 6.5r6.8−19.3%100% | 8.0−72.4%100% | 29−36.7%100% | 46—100% | |
| Shares outstanding | 90,537+70.2%— | 53,187+302%— | 13,234+77.8%— | 7,445+56.4%— | 4,760r3,847+23.7%— | 3,847+71.3%— | 2,246+719685%— | 0.3r1,581−100.0%— | 1,526+29.5%— | 1,178—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | 0.0+250%— | 0.00.0%— | 0.0r0.0−3.1%— | 0.0−53.7%— | 0.0−53.6%— | 0.0−46.4%— | 0.0−15.5%— | 0.0+6.1%— | 0.0—— | |
| Share-based compensation | 2.9+28.7%— | 2.2+95.2%— | 1.2+56.5%— | 0.7r0.7+134%— | 0.3−3.3%— | 0.3−68.9%— | 1.0−36.5%— | 1.6−39.7%— | 2.7−30.5%— | 3.9—— | |
| Cash from operating activities | −11—— | −13—— | −16—— | −22r−22—— | −19—— | −17—— | −13—— | −23r−23—— | −32—— | −25—— | |
| Capital expenditure | — | — | — | — | — | — | 0—— | 0—— | −0.0—— | −0.1—— | |
| Cash from investing activities | — | 0.4—— | — | — | — | — | 0—— | 0−100%— | 10.0—— | −10—— | |
| Debt repaid | −0.6—— | −0.8—— | — | — | — | — | — | — | — | — | |
| Shares issued | 11−9.2%— | 12+68.4%— | 7.0−72.2%— | 25r25+76.3%— | 14−42.9%— | 25+98.0%— | 13+2430%— | 0.5r0.3−96.8%— | 16r17—— | 0—— | |
| Cash from financing activities | 13+19.9%— | 11+56.5%— | 7.0−72.2%— | 25r25+76.9%— | 14−43.0%— | 25+98.2%— | 13+2430%— | 0.5r0.3−96.8%— | 16—— | 0—— | |
| Exchange-rate effect on cash | 0.0—— | −0.0−157%— | 0.0−93.3%— | 0.1r0.1—— | −0.1−170%— | 0.2+488%— | 0.0—— | −0.0—— | −0.1—— | −0.1—— | |
| Change in cash | 2.6—— | −1.2—— | −9.4−342%— | 3.9r3.9—— | −4.7−156%— | 8.3—— | −0.2—— | −22—— | −6.0r−6.0—— | −35r−35—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q1 FY2016to Mar 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 6.7+126%— | 2.1+747%— | 2.1+211%— | 1.5+79.5%— | 1.1*−12.9%— | 0.2+74.1%— | 0.7−79.9%— | 0.8−64.3%— | 1.2*—— | 0.1—— | 3.3—— | 2.3—— | 1.5—— | |
| Selling, general and administrative | 9.4−7.7%— | 2.6+30.1%— | 2.5+3.0%— | 2.2−20.0%— | 2.1*−29.8%— | 2.0+15.6%— | 2.5+9.4%— | 2.7−26.9%— | 3.0*—— | 1.7—— | 2.2—— | 3.7—— | 2.4—— | |
| Operating expenses | — | — | — | 16+347%— | — | — | — | 3.5−41.1%— | — | — | — | 6.0—— | 3.9—— | |
| Operating income | −28—— | −4.7—— | −4.6—— | −16—— | −3.2*—— | −7.4—— | −3.1—— | −3.5—— | −5.3*—— | −2.9—— | −7.4—— | −6.0—— | −3.9—— | |
| Interest and finance income | — | — | — | — | 0*−100%— | 0.0−66.7%— | — | — | 0.0*—— | 0.0—— | 0.0—— | 0.0—— | 0.0—— | |
| Interest expense and finance costs | 0.2−31.3%— | 0.1−15.0%— | 0.1+60.0%— | 0.1+10.9%— | 0*−100%— | 0.1+44.9%— | 0.1−2.0%— | 0.1—— | 0.1*—— | 0.1—— | 0.1—— | — | 0—— | |
| Other non-operating income (expense) | −1.9−178%— | −0.2—— | −0.2−117%— | 0.4—— | −2.0*−232%— | −0.1−363%— | 1.2—— | −0.2−143%— | 1.5*—— | 0.0—— | −0.1—— | 0.4—— | 0.9—— | |
| Income before tax | −30—— | −4.8—— | −4.8—— | −15—— | −5.2*—— | −7.5—— | −1.9—— | −3.7—— | −3.8*—— | −2.9—— | — | — | −3.0—— | |
| Income tax | −0.8—— | 0*—— | 0*—— | −0.9—— | 0.1*—— | −1.1—— | 0—— | 0—— | — | — | — | 0—— | 0—— | |
| Net income attributable to shareholders | −29—— | −4.8—— | −4.8—— | −14—— | −5.3*—— | −6.4—— | −1.9—— | −3.7—— | −3.8*—— | −2.9—— | −7.6—— | −5.6—— | −3.0—— | |
| Earnings per share, basic | — | 0.00—— | 0.00—— | 0.00—— | — | 0.00—— | 0.00—— | 0.00—— | — | 0.00—— | 0.00—— | 0.00—— | -0.00—— | |
| Earnings per share, diluted | — | 0.00—— | 0.00—— | 0.00—— | — | 0.00—— | 0.00—— | 0.00—— | — | 0.00—— | 0.00—— | 0.00—— | -0.00—— | |
| Shares, weighted average (basic) | 265,891+307%— | 265,891+307%— | 143,317+128%— | 118,757+118%— | — | 65,326+168%— | 62,944+234%— | 54,588+306%— | — | 24,386—— | 18,836—— | 13,453—— | 1,178—— | |
| Shares, weighted average (diluted) | 265,891+307%— | 265,891+307%— | 143,317+128%— | 118,757+118%— | — | 65,326+168%— | 62,944+234%— | 54,588+306%— | — | 24,386—— | 18,836—— | 13,453—— | 1,178—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 5.7—15.7% | 5.7+131%15.7% | 7.7+184%19.9% | 2.8+7.2%8.2% | 5.2r0—10.9% | 2.5+10.6%5.5% | 2.7−35.1%5.3% | 2.6+97.1%5.1% | 0r2.6—0.0% | 2.2—82.2% | 4.2—82.3% | 1.3—47.3% | 61—97.6% | |
| Other current assets | 0.1—0.3% | 0.1+102%0.3% | 0.0−54.2%0.1% | 0.0−62.5%0.1% | 0.0−93.0%0.0% | 0.1−42.4%0.1% | 0.1−11.7%0.2% | 0.1−65.5%0.2% | 0.2—0.4% | 0.1—3.4% | 0.1—1.9% | 0.2—8.4% | 1.3—2.0% | |
| Current assets | 6.3—17.2% | 6.3+113%17.2% | 8.3+152%21.6% | 3.6+7.2%10.6% | 5.5+85.0%11.4% | 2.9+7.8%6.5% | 3.3−35.0%6.5% | 3.3+20.8%6.6% | 3.0—5.8% | 2.7—100% | 5.1—100% | 2.8—100% | 63—99.6% | |
| Property, plant and equipment | — | — | — | — | — | — | — | — | — | — | — | — | 0.1—0.1% | |
| Goodwill | — | — | — | — | 8.40.0%17.6% | 8.4—18.6% | 8.4—16.6% | 8.4—16.5% | 8.4—16.7% | — | — | — | — | |
| Other intangible assets | — | — | — | — | — | — | — | — | — | — | — | — | 0.0—0.1% | |
| Total assets | 37—100% | 37−19.4%100% | 39−24.1%100% | 34−33.5%100% | 48−5.3%100% | 45+1560%100% | 51+903%100% | 51+1738%100% | 51—100% | 2.7—100% | 5.1—100% | 2.8—100% | 63—100% | |
| Accounts payable | 9.1—24.7% | 9.1−16.5%24.7% | 9.4−19.0%24.3% | 8.6−33.9%25.5% | 8.8−29.3%18.3% | 11+127%23.9% | 12+148%22.8% | 13+307%25.6% | 12—24.5% | 4.8—175% | 4.7—92.3% | 3.2—116% | 0.6—1.0% | |
| Current liabilities | 13—35.5% | 13−16.6%35.5% | 14−18.7%36.1% | 13−35.8%39.6% | 12−38.0%25.8% | 16+65.1%34.3% | 17+95.2%33.7% | 21+231%41.0% | 20—39.4% | 9.4—345% | 8.8—173% | 6.3—228% | 17—26.3% | |
| Non-current liabilities | — | — | — | — | — | — | — | — | — | — | — | — | 0.1—0.1% | |
| Total liabilities | 19—52.2% | 19−15.9%52.2% | 20−20.9%51.9% | 20−33.2%57.6% | 20−30.9%40.9% | 23—50.0% | 25—49.7% | 29—57.3% | 28—56.0% | — | — | — | 17—26.4% | |
| Retained earnings | −289—−789% | −289—−789% | −284—−735% | −279—−823% | −265—−552% | −259—−571% | −253—−497% | −251—−492% | −247—−489% | −243—−8906% | −241—−4740% | −233—−8406% | −60—−95.0% | |
| Shareholders' equity | 18—47.8% | 18−22.9%47.8% | 19−27.4%48.1% | 14−33.9%42.4% | 28+27.4%59.1% | 23—50.0% | 26—50.3% | 22—42.7% | 22—44.0% | −6.7—−245% | −3.7—−73.0% | −3.6—−128% | 46—73.6% | |
| Total liabilities and equity | 37—100% | 37−19.4%100% | 39−24.1%100% | 34−33.5%100% | 48−5.3%100% | 45+1560%100% | 51+903%100% | 51+1738%100% | 51—100% | 2.7—100% | 5.1—100% | 2.8—100% | 63—100% | |
| Shares outstanding | 182,813—— | 182,813+180%— | 140,033+115%— | 91,567+58.5%— | 90,537+70.2%— | 65,229+169%— | 65,229+169%— | 57,753+262%— | 53,187—— | 24,289—— | 24,289—— | 15,973—— | 1,178—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | 0.0*—— | 0*—— | 0*—— | 0.0—— | — | |
| Share-based compensation | 2.0−44.9%— | 0.5−21.6%— | 0.7−1.1%— | 0.3−70.0%— | 0.5*−62.5%— | 0.7+176%— | 0.7+61.6%— | 1.0+243%— | 1.3*—— | 0.2—— | 0.4—— | 0.3—— | 0.8—— | |
| Cash from operating activities | −13—— | −4.2*—— | −3.1*—— | −2.5—— | −3.0*—— | −2.1*—— | −3.3*—— | −2.2—— | −2.1*—— | −1.5*—— | −4.9*—— | −4.0—— | −7.4—— | |
| Capital expenditure | — | — | — | — | — | — | — | — | — | — | — | — | −0.0—— | |
| Cash from investing activities | — | — | — | — | — | — | — | — | — | — | — | — | −0.0—— | |
| Shares issued | — | — | — | — | 4.8*+54.9%— | 0*—— | 4.8r4.3*−32.5%— | 1.1r1.6−36.8%— | 3.1*—— | −0.1*—— | 7.1*—— | 1.7—— | — | |
| Cash from financing activities | 16+68.6%— | 2.3*+19.9%— | 8.0*+138%— | 0.1−97.5%— | 5.8*+167%— | 1.9*—— | 3.4*−56.4%— | 2.1+40.9%— | 2.2*—— | −0.4*—— | 7.8*—— | 1.5—— | — | |
| Exchange-rate effect on cash | — | — | — | — | 0*−100%— | −0.0*−250%— | — | — | 0.0*—— | 0.0*—— | −0.0*—— | −0.0—— | — | |
| Change in cash | 3.3+994%— | −2.0*—— | 4.9*+3719%— | −2.4—— | 2.7*+558%— | −0.2*—— | 0.1*−95.5%— | −0.0—— | 0.4*—— | −1.9*—— | 2.9*—— | −2.5—— | −7.5—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Akari Therapeutics, PLC operates: 4 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 6 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office3 subsidiaries | — |
| 🇮🇱 Israel | 1 subsidiary | — |
| 🇲🇹 Malta | 1 subsidiary | — |
| 🇨🇭 Switzerland | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at Akari Therapeutics, PLC#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Directors and officers 4 · Material agreement 7 · Agreement ended 2 · New debt 1 · Unregistered share sale 4 · Shareholder rights changed 1 · Shareholder vote 5 · Results announced 3
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder rights changed | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementAgreement endedUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Directors and officersMaterial agreementUnregistered share sale | 8-K | |
| Material agreementAgreement endedNew debt | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 acquisitions
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| Peak Bio | Nov 2024 | Nov 2024 | — | — | Annual report |
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2022 | $13 M | Private placement after listing | $10 to $50 million | 21 | options | SEC |
| Jul 2021 | $12 M | Private placement after listing | $10 to $50 million | 62 | equity, options | SEC |
| Feb 2020 | $10 M | Private placement after listing | $2 to $10 million | 53 | equity, options | SEC |
| Jun 2019 | $5 M | Private placement after listing | $2 to $10 million | 45 | options | SEC |
| Sep 2015 | $75 M | Private placement after listing | $50 to $250 million | 28 | equity | SEC |
| Sep 2013 | $13 M | Private placement after listing | $10 to $50 million | 18 | equity | SEC |
| Nov 2012 | $2 M | Private placement after listing | Under $2 million | 20 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 67% of workforce | Restructuring planSEC 8-K | “On May 1, 2024, Akari Therapeutics, Plc (the “Company”) began to implement a reduction-in-force of approximately 67% of its total workforce as a result of the recently announced pr…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Akari Therapeutics, PLC compares in Biotechnology
- Market cap$13 M · higher than 13% of 726
- Revenue growth-39.3% · higher than 24% of 438
- Price / book0.5× · lower than 93% of 534
- FCF yield-126.4% · higher than 7% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Akari Therapeutics, PLC🇺🇸 | $13 M | — | — | -39.3% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 1, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Akari Therapeutics, PLC? Verify and update this profile — free
Show Akari Therapeutics, PLC's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.